xCELLigence RTCA eSight

In this application note, Agilent Technologies presents the evaluation of 1,3-diphenylguanidine (DPG) and five of its chlorinated derivatives’ effects on cell heath and bioenergetics using the Agilent xCELLigence RTCA eSight and Agilent Seahorse XF96 extracellular flux analyzer. 1-(2,4-dichlorophenyl)-3-phenylguanidine (CC15) and 1-(4-chlorophenyl)-3-(2,4-dichlorophenyl) guanidine (CC11) were the least and most cytotoxic compounds, respectively, except for DPG, which was the most cytotoxic. Real time cell analysis (RTCA) results were similar to traditional alamarBlue cell viability assay results. The Seahorse XF96 analyzer results indicated that, except for 1,3-bis-(2-chlorophenyl) guanidine (CC04), all of the DPG compounds tested had adverse effects on cell bioenergetics. While the compounds’ limited effects on mitochondrial basal respiration and ATP production might be short lived, the significant effect on proton leakage suggested irreversible mitochondrial damage.

As cell analysis in basic research, translational medicine, and cell therapies becomes ever more sophisticated, it is imperative that solutions provide multiparametric and data-rich information. In this application note, Agilent Technologies introduces its xCELLigence RTCA eSight for real-time cell analysis, featuring non-invasive impedance-based monitoring together with live-cell imaging, all inside your incubator. One experiment provides two simultaneous methods with 5 different readouts. Cellular impedance first provides sensitive and rapid information about cell viability, growth, morphology, and barrier function. Brightfield and three fluorescent channels monitor and quantify viability, toxicity, and apoptosis- validating cellular impedance readouts and further boosting confidence in your results. This combination of information enables for much wider sampling and the assessment of cellular processes and biology – all within a single experiment.

Uncover the latest recommendations from leaders in immunotherapy research and their insights into exciting new immunotherapy developments. This eBook showcases new analysis tools for scientists developing innovative cell-based solutions.

Explore functional potency assays for cancer immunotherapy research. This handbook includes topics such as antibody-dependent cell-mediated cytoxicity (ADCC), BiTEs, bispecific antibodies, checkpoint inhibitors, CAR-T cells and more.

Join Professor Mercedes Rincon, University of Colorado Anschutz School of Medicine, as she discusses the groundbreaking advancements in adoptive T cell therapy, particularly chimeric antigen receptor (CAR) T cell therapy. While CAR-T therapy has achieved impressive complete remission rates in 60–90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r-B-ALL), challenges such as treatment failures and relapses remain significant obstacles.

Metabolism plays a critical role in T cell function, shaping immune responses. While glycolysis is essential for T cell expansion, it can restrict the self-renewal capacity of CAR-T cells during manufacturing. Mitochondrial respiration is vital for their survival and effectiveness. Recent findings have highlighted MCJ, a protein that negatively regulates mitochondrial function in CD8 cells. Loss of MCJ enhances mitochondrial respiration, cytokine secretion, and anti-tumor activity. Targeting MCJ to boost mitochondrial metabolism presents a promising strategy to enhance the efficacy of CAR-T cells and advance adoptive T cell therapies.

Key learning objectives

• Understand the current landscape of adoptive T-cell therapy
• Explain the role of metabolism in T cell function, highlighting the significance of glycolysis and mitochondrial respiration in enhancing CAR-T cell efficacy
• Identify the potential of MCJ as a therapeutic target to improve mitochondrial metabolism, cytokine secretion, and overall effectiveness of CAR-T cell therapies

Who should attend?

• Researchers and scientists specializing in CAR T-cell therapy, immunotherapy development, cell metabolism, glycolysis, and mitochondrial respiration.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a promising therapeutic approach for several cancers. Despite the growing interest, the widespread use of CAR T-cell therapies has been restricted due to their high cost and the challenges that arise when compared with traditional methods for manufacturing and product QC. Developing sensitive and reliable analytics to characterize CAR-T products' critical quality attributes (CQAs) and tailoring the cell expansion process to achieve these CQAs provides tools for a more consistent manufacturing process.

Join Dr. Laurissa Ouaguia, Scientist, Reagents and Application Development, Agilent Technologies, as she discusses Agilent’s portfolio of cell analysis tools. She will also demonstrate how they can be applied during the production of CAR T-cells using the functionally closed and automated Lonza Cocoon® Platform for cell manufacturing. This approach provides a deeper understanding of the immune phenotype, metabolic fitness, and cytotoxic function of the CAR T-cells throughout the production, allowing for more informed process development.

Key learning objectives

• Explore the Agilent Seahorse XF Analyzer for real-time live-cell metabolic assay and the impedance-based xCELLigence RTCA eSight system for real-time immune cell killing potency assay.
• Understand how Agilent cell analysis platforms deliver reliable, reproducible, and sensitive analytics, providing a deeper understanding of CAR T-cells' immune phenotype, metabolic fitness, and cytotoxic function throughout the production in an automated cell manufacturing platform
• Discover how enhanced analytics can provide valuable tools for in-process analysis during CAR T-cell manufacturing, potentially shortening production timelines and reducing associated costs

Who should attend?

• Researchers and scientists specializing in cell therapy
• Experts in cell therapy analytics and process development
• Cell therapy manufacturing specialists
• Quality control (QC) professionals in the cell therapy field
• Professionals in the pharmaceutical and biopharmaceutical industries focusing on cell therapy

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Watch this on-demand webinar to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours

Learn how high-throughput, real-time cell analysis can accurately detect and quantify virus-neutralizing antibodies and see how this technology is advancing COVID-19 research

Join us on Wednesday, August 26, to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours

Bruker, FortéBio, Biotix and Molecular Devices among the manufacturers recognized in San Diego